Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary
This retrospective analysis supports incorporating CancerTYPE ID into the evaluation for patients with CUP to help determine the tissue of origin and identify actionable genetic alterations. This approach may allow more patients with CUP to benefit from site-specific FDA-approved targeted therapies or enrollment into clinical trials.
Authors
- Catherine A. Schnabel (ORCID: https://orcid.org/0009-0006-5500-9290)
- Jenna Wong (ORCID: https://orcid.org/0009-0008-3211-5343)
- Harry E Fuentes (ORCID: https://orcid.org/0000-0002-7837-8359)
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- Kai Treuner (ORCID: https://orcid.org/0009-0006-3443-3578)
- James A. Reeves (ORCID: https://orcid.org/0000-0001-9690-7341)
- Pashtoon Murtaza Kasi (ORCID: https://orcid.org/0000-0002-5169-7085)
- Þorvarður R. Hálfdánarson (ORCID: https://orcid.org/0000-0001-8460-1257)
- Li Ma (ORCID: https://orcid.org/0000-0002-5444-5262)
- Frank A. Greco (ORCID: https://orcid.org/0000-0003-2802-3741)
- Lowell L. Hart
Institutions
- Cornell University (US)
- Sarah Cannon (US)
- Biothera (United States) (US)
- Hologic (United States) (US)
- Mayo Clinic in Arizona (US)
- Tennessee Oncology (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/po.24.00191
- Citations
- 4
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- American Society of Clinical Oncology
- Celgene
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Jazz Pharmaceuticals
- Aeglea BioTherapeutics
- Celldex Therapeutics
- Novocure
- PTC Therapeutics
- Ionis Pharmaceuticals
- Tizona Therapeutics
- Agios Pharmaceuticals
- BeiGene
- Incyte
- Calithera Biosciences
- Tarveda Therapeutics
- Advanced Accelerator Applications
- Apollomics
- Moderna
- MacroGenics
- G1 Therapeutics
- Seagen
- Natera
- Eisai
- Astellas Pharma
- Servier
- Ipsen
- Genentech
- EMD Serono
- Foundation Medicine
- Daiichi Sankyo Europe